The objective of this study was to evaluate the value of using digital rectal examination (DRE) for prostate cancer diagnosis in an Asian population. Patients with serum prostate-specific antigen (PSA) levels ranging from 2.5 to 19.9 ng/ml underwent transrectal ultrasonography-guided prostate biopsies. Patients were divided into two groups: the normal DRE group (n ¼ 721) and the abnormal DRE group (n ¼ 192). The cancer detection rate was higher in the abnormal DRE group (47.4%) than in the normal DRE group (23.0%) (Po0.001). However, the detection rates in these two groups were not significantly different in men 45-59 years old as well as in men with low PSA levels (2.5-3.9 ng/ ml). In all subjects, the areas under the receiver operating characteristic curves for positive biopsies were 60.0% (95% confidence interval (CI), 55.7-64.3%, Po0.001). However, in the subgroup analysis, the predictive power of the DRE was not significant in men 45-59 years old. In addition, DREs of patients with low PSA levels had no discriminative ability. The pathological features of the prostate biopsies were not significantly different between the two groups in subjects 45-59 years old and in subjects with PSA levels from 2.5 to 3.9 ng/ml. Our data indicate that DREs increase the probability of cancer detection. However, our findings also raise the question, 'Are DREs really useful for cancer detection in younger men and men with low PSA levels in the Asian population?'
Introduction
Screening for prostate cancer remains a controversial issue as it has not been proven to reduce disease-specific mortality. However, there is general agreement among clinicians that prostate-specific antigen (PSA) screening can detect early-stage prostate cancer and that most cancers detected by PSA screening appear to be clinically important when their pathological characteristics are used as a surrogate for biological potential. 1 Prostate cancer screening generally consists of an annual digital rectal examination (DRE) and serum PSA determination. However, several investigators have suggested that the initial prostate cancer-screening test by DRE may be replaced by screening using only serum PSA. 2, 3 PSA reference ranges differ significantly according to the race of the patient. [4] [5] [6] However, no substantial differences in PSA levels between native Japanese and Japanese-American men have been found, even though there are substantial differences in prostate cancer incidence between these two groups. 7 Thus, the results of a study conducted in Western countries may not directly translate into Asian practice, because of different patterns of practice (screening, referral, etc.) and racial differences with regard to the incidence of prostate cancer. 8 To date, there is only a limited amount of information on the significance of using DREs for prostate cancer diagnosis among Asian men. The objective of this study was to evaluate DREs for prostate cancer diagnosis in Korean men. We evaluated the cancer detection rate and the pathological findings from the biopsies of this patient population that had PSA levels ranging from 2.5 to 19.9 ng/ml.
Methods
We reviewed the records of 1369 patients undergoing transrectal ultrasonography (TRUS)-guided prostate biopsies at three hospitals. Patients with ages ranging from 45 to 79 years, who visited the Department of Urology, were entered into the study. We enrolled individuals who visited our department for a variety of reasons including prostate cancer screening and voiding symptoms, regardless of whether the visit was primary or referred. All men underwent detailed clinical examinations, including DRE and transrectal ultrasonography.
Total PSA serum levels of each patient were quantified by immunoradiometric assay (Izotop, Budapest, Hungary). Blood samples were obtained before the patients were examined by a physician. All the blood samples were stored at À701C for less than 1 week before being assayed for serum PSA concentration. Patients with an abnormal DRE and/or serum PSA levels greater than 2.5 ng/ml underwent a TRUS-guided needle biopsy after giving a written informed consent. The DRE findings were characterized as abnormal in the presence of prostate induration and/or nodularity. Transaxial and sagittal scanning of the prostate was performed by an experienced radiologist using a 7.0-MHz transducer (Ultramake 9, ATL Inc., Washington, USA). In specimens diagnosed as prostate cancer, we performed an additional review of the Gleason score, maximal cancer length, percentage of cancer core (number of cores involved with cancer divided by the total number of biopsy cores), cancer length per biopsy core (total millimeters of cancer in the biopsy specimen divided by the total number of biopsy cores) and percentage of cancer length (total millimeters of cancer in the biopsy specimens divided by total millimeters of biopsy specimens).
As the age-specific reference ranges were lower for serum PSA levels in Asian men than Caucasian men 6, 9 and a lower PSA cutoff should be considered as an indication for prostate biopsy in the Asian population, [10] [11] [12] [13] we excluded men who had a serum PSA less than 2.5 ng/ml from the analysis. In addition, to reduce the likelihood of including men with occult prostate cancer that can affect serum PSA values, we excluded men from the analysis who had a serum PSA greater than 20 ng/ml. Men were also excluded if they had previously undergone a prostate biopsy, had received a prior diagnosis of prostate cancer, had undergone prostate surgery or radiation treatment, had received 5a-reductase inhibitors, had acute urinary retention or an indwelling catheter, had a duration of more than 3 months between PSA measurement and biopsy or had evidence of an acute urinary infection (pyuria and bacteriuria) upon urinalysis. A total of 913 men met these criteria and constituted the study cohort. This cohort had a median age of 66 years (range 45-79). The median prostate volume of the patients was 43.6 cm 3 (range 10-183.6) and their serum PSA levels ranged from 2.5 to 19.9 ng/ml (median 6.5).
The continuous variable values are presented as the median (5th-95th percentiles) and rates are expressed as percentages (%). Patients were divided into two groups: patients with normal DREs (n ¼ 721) and patients with abnormal DREs (n ¼ 192). Data comparisons were made using the w 2 test or the Armitage test for categorical variables and the Mann-Whitney U-test for continuous variables. The receiver operating characteristic (ROC) curve was used to indicate the ability of the DRE to predict a positive biopsy. Areas under the ROC curve were estimated. All statistical tests had a 5% significance level and were two-sided. The statistical software package SPSS 10.0 (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses.
Results
Patient characteristics according to the DRE results are shown in Table 1 . The abnormal DRE group was significantly older (P ¼ 0.022), had higher PSA levels (P ¼ 0.020) and density (Po0.001) and had smaller prostates (P ¼ 0.016). The two groups had no statistically significant differences in the number of cores per biopsy or core density (number of cores divided with prostate volume).
The detection rate increased with advancing age; 16.3% (17 of 106) for men 45-59 years old, 25.0% (116 of 464) for men 60-69 years old and 39.8% (115 of 289) for men 70-79 years old (Po0.001). In addition, the detection rate increased dramatically in patients with greater serum PSA levels. The detection rate was 16.0% (17 of 106), 25.3% (152 of 600) and 42.5% (88 of 207) in subjects with PSA levels ranging from 2.5 to 3.9, 4.0 to 9.9 and 10.0 to 19.9 ng/ml, respectively (Po0.001). The detection rate decreased in patients with larger prostates: 41.9% (112 of 267) for prostate volumes less than 35 g, 28.0% (100 of 357) for prostate volumes ranging from 35 to 54.9 g and 15.6% (45 of 289) for prostate volumes greater than 55 g (Po0.001). The cancer detection rate was 23.0% (166 of 721) in men with normal DREs and 47.4% (91 of 192) in those with abnormal DREs. For subjects 60 years or older, the cancer detection rate was higher in the abnormal DRE group than the normal DRE group (Po0.001); however, for men aged 45-59 years, the detection rate was not significantly different between the two DRE groups. Furthermore, in patients with inter- DRE as a prostate cancer-screening method HB Shim et al mediate (4.0-9.9 ng/ml) and high (10.0-19.9 ng/ml) PSA levels, the cancer detection rate was significantly higher in the group with abnormal DREs than in the normal DRE group (Po0.001), but no significant difference was found between the two groups in the patients with low PSA levels (2.5-3.9 ng/ml) ( Table 2 ). The predictive power of the DRE is shown in Table 3 . In all subjects, the areas under the ROC curves for positive biopsies were 60.0% (95% CI, 55.7-64.3%, Po0.001). However, in the subgroup analysis, the predictive power of the DRE was not significant in men 45-59 years old. In addition, DREs had no discriminative ability in patients with low PSA levels. Table 4 shows the biopsy results of patients with prostate cancer. The abnormal DRE group was significantly greater than the normal DRE group with regard to the number of cancer cores (P ¼ 0.005), percentage of cancer cores (P ¼ 0.003), maximal cancer length (P ¼ 0.032), total cancer length (P ¼ 0.009), cancer length per biopsy core (P ¼ 0.010) and percentage of cancer lengths (P ¼ 0.003). However, no statistically significant differences between the two groups were found in the Gleason score. In the subgroup analysis, no significant differences were found between the two groups in subjects 45-59 years old except in the percentage of cancers (P ¼ 0.041) and for the number of subjects with PSA levels in the range of 2.5-3.9 ng/ml.
Discussion
PSA and DRE screening provides greater sensitivity than PSA alone. Prostate biopsies are routinely recommended for patients with abnormal DRE, regardless of serum PSA levels, and for patients with normal DRE and PSA levels higher than 4 ng/ml. For a population-based screening program, compliance to the screening tests and avoidance of unnecessary testing are prerequisites, as the increased participation rate resulting from PSA screening alone may result in a greater detection rate. Nagler et al.
14 demonstrated that DRE was a significant barrier to participation in prostate cancer screening.
There is disagreement over which PSA levels should prompt a prostate biopsy. Recent research supports lowering the PSA threshold values to 2.5 ng/ml in order DRE as a prostate cancer-screening method HB Shim et al to double the detection rate of prostate cancer. 15 However, improved specificity is important, especially in Asian men with low PSA levels, as many do not have prostate cancer. Unless the specificity can be improved, decreasing the PSA threshold may lead to many unnecessary biopsies because this population has inherently lower PSA levels. 16, 17 In addition, it is still unclear whether the prostate cancer observed in Asian men with lower PSA levels (i.e. o4.0 ng/ml) is significant. Similar findings have been reported in both Caucasian and Black men.
In our study of men with low PSA levels, the cancer detection rate was not significantly different in men with normal DREs and in men with abnormal DREs. However, Potter et al. 18 found that DRE status had a large influence on the likelihood of positive biopsies across all PSA and age ranges and suggested that a combination of PSA, DRE and age could better define the probability of a positive biopsy than any factor alone. On the contrary, several studies have recently challenged the value of DREs in the detection of prostate cancer. Catalona et al. examined 10 523 men screened for prostate cancer and concluded that the DRE had a poor predictive value (12.8%) and sensitivity in the low PSA range (0.0-3.9 ng/ ml). In addition, Ohi et al. 20 reported that the cancer detection rate was not significantly different in subjects with (9 of 38, 23.7%) and without (6 of 31, 19.4%) abnormal DREs at PSA levels between 2.1 and 4.0 ng/ml. Furthermore, Punglia et al. 15 reported similar results and found that the DRE had little prospect to benefit prostate cancer detection. Therefore, the DRE has a poor performance in low PSA ranges. These findings call into question the value of DREs in prostate cancer screening because most prostate cancers are found in patients with a PSA level greater than 4.0 ng/ml.
A study by Carter et al. 21 on men of similar age with non-palpable prostate cancer found that the proportion of men with curable prostate cancer changed minimally (from 2 to 4%) when they had pretreatment PSA levels between 2.6 and 6.0 ng/ml. However, at any given pretreatment PSA level, a younger age was a strong DRE as a prostate cancer-screening method HB Shim et al predictor of curable cancer among men with nonpalpable disease. These data suggest that endeavoring to detect prostate cancer in younger men may be a more effective method of reducing cancer mortality than lowering the PSA threshold to less than 4.0 ng/ml. In our cohorts, the cancer detection rate was not significantly different between the two groups in men 45-59 years old, although the detection rate was higher in the abnormal DRE group than in the normal DRE group in men 60 years or older. Some of our study results were different from previous findings. Although there is a consensus that the positive predictive value of the DRE increases with increasing PSA levels, the influence of other patient characteristics such as age and prostate volume on the value of the DRE remains controversial. In our study, the cancer detection rate in patients with an abnormal DRE increased with advancing age, whereas this rate decreased in men with larger prostates. On the contrary, Issa et al. 22 demonstrated that the positive predictive value of the DRE was similar (45-50%) with regard to prostate volume, although the specificity and the negative predictive value of the DRE showed moderate improvement in the presence of a substantially enlarged prostate (460 cm 3 ). In addition, in their study, age did not influence the positive predictive value of the DRE except in men aged 80-89 years. We found no statistically significant differences between the two groups with regard to Gleason scores. However, Gosselaar et al. 23 reported that DRE detected more selectively high-grade cancers. Furthermore, a population-based case-control study of screening and prostate cancer mortality in Olmsted County revealed that men who were screened by DRE were less likely to die from the disease than men who were not screened. 24 These findings are difficult to interpret, although a number of possible explanations for our results exist. These studies all have differences in terms of study design, inclusion and exclusion criteria and a true difference in the incidence of prostate cancer among different countries. In addition, these differences may be due to the methods by which the studies were conducted, interpretations of the DREs or the methods for inviting a screening population.
It is important to note that our study was not community-based. Our aim was not to estimate the epidemiological incidence of prostate cancer, but rather to evaluate the value of DREs in our daily practice for prostate cancer detection in men with voiding symptoms. However, the predictive value of the screening tests may be different in patients presenting with symptoms as opposed to the general population. Thus, our data cannot be applied to population-based screening. In addition, our results relate to a specific group of men, and different ethnicities may behave somewhat differently because serum PSA levels are race-dependent as well as age-dependent. Furthermore, in this study, biopsy protocols were not standardized. Although increasing the number of biopsy cores either only marginally enhanced the overall detection of prostate cancer 25 or did not significantly improve the cancer detection rate; 26, 27 in Asian men, different biopsy schemes might influence our results. Finally, our data indicate that tumor aggressiveness may be associated with DRE status. However, definitions of what might be an aggressive disease are likely not to be applicable to the individual patient. Without being able to correlate these findings to important end points, such as prostate cancer mortality, it will be impossible to determine what may be a clinically important cancer.
Overall, our data indicate that DRE increases the probability of cancer detection and that cancer associated with an abnormal DRE has a greater probability of having more aggressive characteristics. However, our findings raise the following question: 'Are DREs really useful for cancer detection in younger men and men with PSA levels ranging from 2.5 to 3.9 ng/ml in a country with a low incidence of prostate cancer?'
